Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report

Journal of Personalized Medicine

Steven R. Schuster²  Barbara A. Pockaj³  Mary R. Bothe²  Paru S. David¹ 

[1]Department of Womens Health, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA

[2] E-Mail:

[3]Division of Hematology and Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA

[4] E-Mails:

[5]Department of Surgery, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA

[6] E-Mail:

关键词: breast cancer;    genomic profiling;    medical decision-making;    Oncotype DX;    chemotherapy;    personalized medicine;   

DOI  :  10.3390/jpm2030071

来源: mdpi

【 摘 要 】

Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple tools that help individualize the treatment options for a patient. Population-based analysis with Adjuvant! Online and genomic profiling with Oncotype DX are two commonly used tools in patients with early stage, node-negative breast cancer. This case report illustrates a situation in which the population-based prognostic and predictive information differed dramatically from that obtained from genomic profiling and affected the patient’s decision. In light of this case, we discuss the benefits and limitations of these tools.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.